New antibody for lung scarring passes first safety check in healthy volunteers
NCT ID NCT06310746
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a single dose of HLX6018, an experimental antibody, in 66 healthy adults to see if it is safe and how the body handles it. HLX6018 is designed to block a protein pathway involved in idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. Because this is the first human trial, it only looks at safety and drug levels—not whether it actually treats IPF.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HLX6018 (a monoclonal antibody that targets GARP/TGF-β1)
- What this could lead to
- If this early safety study goes well, it could pave the way for testing HLX6018 as a potential treatment for idiopathic pulmonary fibrosis (IPF), a serious lung disease.
- What could go wrong
- This is a very early Phase 1 trial in healthy people, not patients. It only checks safety and dosing—not whether the drug works for IPF. Many drugs fail in later stages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Hospital of Jilin University
Changchun, Jilin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a breath test predict lung scarring? new study seeks answers
- New inhaled drug for lung disease tested in healthy people first
- New hope for lung scarring: HSK44459 enters final trial phase
- Healthy volunteers to test experimental lung disease drug
- New drug for lung scarring takes first step in healthy volunteers
- Simple questionnaire could bring palliative care home for lung disease patients